Article
Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
Breast cancer research : BCR - 15 Mar 2012
Knappskog Stian, Chrisanthar Ranjan, Løkkevik Erik, Anker Gun, Østenstad Bjørn, Lundgren Steinar, Risberg Terje, Mjaaland Ingvil, Leirvaag Beryl, Miletic Hrvoje, Lønning Per E
Abstract excerpt
INTRODUCTION: Mutations affecting p53 or its upstream activator Chk2 are associated with resistance to DNA-damaging chemotherapy in breast cancer. ATM (Ataxia Telangiectasia Mutated protein) is the key activator of p53 and Chk2 in response to genotoxic stress. Here, we sought to evaluate ATM's potential role in resistance to chemotherapy. METHODS: We sequenced ATM and assessed gene expression levels in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.